The main aim of this study was to develop a topical drug delivery (Organogel) of Luliconazole to reduce the dose of the active drug, to improve patient compliance, to avoid the side effects and increase local onset absorption and action. Luliconazole is an optically active imidazole antifungal agent. It has been found to have broad-spectrum of antifungal activity against pathogenic fungi, especially dermatophytes. Methods: Topical Organogel formulations of Luliconazole were prepared using span-60 with different penetration enhancer with their different concentrations. Six different formulations of Luliconazole were prepared and evaluated with respect to their colour, Spreadability, viscosity parameter, determination of pH, drug content, in vitro drug release studies, zeta potential studies, and stability studies. Results: FT-IR study revealed that there were no any significant interaction between the drug, excipients and polymers. All the designed formulations of Luliconazole show acceptable standard physical properties. The drug content and percentage yield were higher for F2 formulation among all formulation F2 shows better drug release. Stability study of the best formulation F2 (Coconut oil) shows that there was no difference in drug content and in vitro drug release studies. Conclusion: From the above observation results that this F2 formulation (Coconut oil) may be more encouraging topical substitute for the healing of fungal infections in the skin.

Introduction: Life expectancy has grown as a result of improvements in care, such as the advent of antiretroviral medication (ART) for the treatment of individuals infected with HIV. However, there is a growing pattern of comorbidity between these individuals and those who are HIV-negative³. The long-standing question is whether the increasing life expectancy among People living with HIV (PLWH) has any bearing on the development of comorbidities that are not directly related to HIV. Present study was planned to assess & compare demographics, clinical history & QOL amongst HIV infected people associated with comorbidity & free from comorbidity. Materials and Methods: Present study is a cross-sectional prospective study conducted from duration March 2023 to March 2024. 30 Patients of HIV infection associated with comorbidity (Group A) & 30 without comorbidity (Group B) of all age groups & both genders were enrolled. After obtaining their demographic data & clinical history, their quality of life was assessed through WHO based questionnaire. Data compiled & statistically assessed. Observations and Results: Mean age was 43±15.75 in Group A & 40.23±11.95 in Group B.Dominant comorbidity found in study were Hyperlipidaemia in 14 (46%). Fair (< 65%) Level of Quality of life was observed in 3 (5 %) participants & all of which were from comorbid group (Group A). Satisfactory (65% to 85%) level was found in 33 (55%) whereas Good (> 85%) level was found in 24 (40%). Conclusion: Present study findings Can help persons living with the disease to adopt lifestyles healthy enough to help them live close to normal healthy, quality lives.